Follow The Filings

Insider trades

Stock that executives, directors and 10% owners bought and sold on the open market, from the Form 4s they file with the SEC within two business days. Grants, option exercises and shares sold to cover taxes are left out.

4,839 companies covered, latest filing Oct 23.

  • $1.5B bought by 341 insiders at 208 companies
  • $3.2B sold by 266 insiders outside a trading plan
  • $7.9B sold by 827 insiders under 10b5-1 plans
  • 10 companies where two or more insiders bought (30 days)

Biggest buys

Past month, each insider's filings added up.

  1. LENLennar
    Berkshire Hathaway Inc.10% owner, +1 joint filer
    4,758,747 shares at $80.46 Sep 23–Oct 2, 3 filings 3 superinvestors bought in Q2
    $383M
  2. CRBGCorebridge Financial
    Life Insurance Co Nippon10% owner
    6,596,299 shares at $34.18 Sep 21–Oct 20, 21 filings +5.3% to stake 2 superinvestors bought in Q2
    $225M
  3. KODKodiak Sciences
    Baker Bros. Advisors LPDirector, +5 joint filers
    1,941,755 shares at $80.85 Sep 28–29, 3 filings +11% to stake 1 superinvestor sold in Q2
    $157M
  4. SAFXXCF Global
    EEME Energy SPV I, LLC10% owner
    119M shares at $1.19 Oct 16 +109% to stake
    $142M
  5. GPIGroup 1 Automotive
    Conifer Management, L.L.C.10% owner
    400,000 shares at $244.51 Sep 24–30, 2 filings +26% to stake 2 superinvestors bought in Q2
    $97.8M
  6. UUUUniversal Safety Products
    Milton C Ault IIIDirector
    33,434 shares at $2,766.36 Sep 21–30, 2 filings
    $92.5M
  7. GMEGameStop
    Ryan CohenCEO
    1,994,130 shares at $25.29 Sep 29–Oct 13, 3 filings +4.9% to stake
    $50.4M
  8. BORRBorr Drilling
    Tor Olav TroimDirector
    9,500,000 shares at $4.53 Oct 5–15, 7 filings +31% to stake
    $43M
  9. PAMPampa Energia
    Marcos Marcelo MindlinDirector
    435,000 shares at $80.78 Oct 15 +6.4% to stake
    $35.1M
  10. GGRGogoro
    Chung-Yao YinDirector
    14.2M shares at $2.48 Oct 7 New stake
    $35.1M

Biggest sales

Past month, each insider's filings added up. Planned sales are marked.

  1. IHTInnSuites Hospitality Trust
    James F WirthCEO
    86,222 shares at $48,532.59 Oct 7–20, 2 filings 1.1% of stake Planned sale (10b5-1)
    $4.2B
  2. MDLNMedline
    GIC Private Ltd10% owner, +2 joint filers
    28.5M shares at $34.97 Oct 2–8, 2 filings
    $996M
  3. ESTCElastic
    Steven SchuurmanDirector
    3,500,000 shares at $92.43 Oct 5–12, 2 filings 58% of stake
    $323M
  4. TALOTalos Energy
    Empresarial De Capitales S.a. De C.v. Control10% owner
    14.6M shares at $17.33 Oct 6–19, 5 filings 37% of stake
    $253M
  5. AVGOBroadcom
    Henry SamueliDirector
    702,190 shares at $356.04 Sep 23 1.9% of stake Planned sale (10b5-1)
    $250M
  6. THTarget Hospitality
    TDR Capital II Investments LP10% owner, +9 joint filers
    11M shares at $18.40 Oct 1 40% of stake
    $202M
  7. ANETArista Networks
    Jayshree UllalCEO
    778,531 shares at $213.68 Sep 25–Oct 9, 4 filings 4.8% of stake Planned sale (10b5-1)
    $166M
  8. KNTKKinetik
    ISQ Global Fund II GP LLC10% owner, +4 joint filers
    2,448,272 shares at $54.63 Sep 22–Oct 13, 4 filings 100% of stake
    $134M
  9. CRWDCrowdStrike
    Burt W. PodbereCFO
    480,000 shares at $261.44 Sep 24 Planned sale (10b5-1)
    $125M
  10. NBISNebius Group
    Ophir NaveCOO
    500,000 shares at $235.53 Oct 5 52% of stake Planned sale (10b5-1)
    $118M

Cluster buying

Companies where two or more insiders bought on the open market in the last 30 days, most buyers first

  1. TSMTaiwan Semiconductor 19 insiders, $80K

    Che-Chia Wei CEO, Yuh-Jier Mii COO, Yung-Pei Chin COO, Yung-Chin Hou COO, +15 more

    Latest buy Oct 7 19 executives 20 superinvestors sold in Q2
  2. SPGSimon Property Group 11 insiders, $461K

    Reuben S Leibowitz Director, Larry C Glasscock Director, Daniel C. Smith Director, Gary M Rodkin Director, +7 more

    Latest buy Sep 30
  3. FULH. B. Fuller 9 insiders, $1.1M

    R Jeffrey Bailly Director, Daniel L Florness Director, Srilata Zaheer Director, Charles T Lauber Director, +5 more

    Latest buy Oct 16 1 executive 1 superinvestor bought in Q2
  4. RAPPRapport Therapeutics 5 insiders, $1.6M

    Steven M Paul Director, John Maraganore Director, Troy A. Ignelzi CFO, Wendy B. Young Director, +1 more

    Latest buy Oct 22 1 executive
  5. ATCHAtlasClear 5 insiders, $163K

    Thomas Jon Hammond Director, Sandip I Patel CFO, John Martin Schaible Chair, David Craig Ridenhour President, +1 more

    Latest buy Sep 25 3 executives
  6. RGCORGC Resources 5 insiders, $85K

    John B Williamson III Director, Robert B Johnston Director, Paul W Nester CEO, Lawrence T. Oliver Senior VP and Secretary, +1 more

    Latest buy Oct 1 3 executives
  7. WVVIWillamette Valley Vineyards 5 insiders, $75K

    Michael Jordan Osborn CEO, John Walter Hazlett CFO, Gregory William Voorhies Director, James W Bernau President, +1 more

    Latest buy Oct 12 3 executives
  8. MPBMid Penn Bancorp 5 insiders, $25K

    Matthew G De Soto Director, Albert J. Evans Director, Kimberly J Brumbaugh Director, Theodore W Mowery Director, +1 more

    Latest buy Sep 30
  9. DXDynex Capital 4 insiders, $245K

    Smriti Laxman Popenoe CEO, Byron L Boston CEO, Terrence John Connelly Jr. Chief Investment Officer, Michael Andrew Sartori CFO

    Latest buy Oct 20 4 executives
  10. ANIXAnixa Biosciences 4 insiders, $203K

    Lewis H Titterton Jr. Director, Amit Kumar CEO, Michael Catelani CFO, Arnold M Baskies Director

    Latest buy Oct 22 2 executives

RXRX insider trades

Every open-market buy and sale in RXRX, one row per filing, newest first

RXRX page
All Buys Sales
Everyone CEOs CFOs Executives Directors 10% owners
Any size $100K+ $1M+ $10M+
Hide planned sales
  1. Blake Borgeson Director
    RXRXRecursion Pharmaceuticals
    Planned sale
    $242K 50,000 shares at $4.84 0.8% of stake
    Traded Oct 6 Filed Oct 7
    ↗
  2. Robert Hershberg Director
    RXRXRecursion Pharmaceuticals
    Planned sale
    $125K 25,000 shares at $5.00 13% of stake
    Traded Oct 6 Filed Oct 7
    ↗
  3. Najat Khan CEO
    RXRXRecursion Pharmaceuticals
    Planned sale
    $79K 22,408 shares at $3.52 1.1% of stake
    Traded Sep 8 Filed Sep 10
    ↗
  4. Blake Borgeson Director
    RXRXRecursion Pharmaceuticals
    Planned sale
    $100K 30,000 shares at $3.34 0.5% of stake
    Traded Sep 1 Filed Sep 2
    ↗
  5. Blake Borgeson Director
    RXRXRecursion Pharmaceuticals
    Planned sale
    $98K 30,000 shares at $3.25 0.5% of stake
    Traded Aug 4 Filed Aug 6
    ↗
  6. Blake Borgeson Director
    RXRXRecursion Pharmaceuticals
    Planned sale
    $159K 40,000 shares at $3.96 0.6% of stake
    Traded Jul 7 Filed Jul 9
    ↗
  7. Namandje Bumpus Director
    RXRXRecursion Pharmaceuticals
    Planned sale
    $13K 3,963 shares at $3.18 3% of stake
    Traded Jun 18 Filed Jun 22
    ↗
  8. Christopher Gibson Director
    RXRXRecursion Pharmaceuticals
    Planned sale
    $145K 40,000 shares at $3.62 4.3% of stake
    Traded Jun 5 Filed Jun 5
    ↗
  9. Najat Khan CEO
    RXRXRecursion Pharmaceuticals
    Planned sale
    $84K 23,588 shares at $3.58 1.1% of stake
    Traded Jun 5 Filed Jun 5
    ↗
  10. Namandje Bumpus Director
    RXRXRecursion Pharmaceuticals
    Planned sale
    $16K 4,386 shares at $3.54 9.2% of stake
    Traded Jun 3 Filed Jun 4
    ↗
  11. Blake Borgeson Director
    RXRXRecursion Pharmaceuticals
    Planned sale
    $110K 30,000 shares at $3.68 0.5% of stake
    Traded Jun 2 Filed Jun 4
    ↗
  12. Christopher Gibson Director
    RXRXRecursion Pharmaceuticals
    Planned sale
    $123K 40,000 shares at $3.08 4.3% of stake
    Traded May 22 Filed May 27
    ↗
  13. Christopher Gibson Director
    RXRXRecursion Pharmaceuticals
    Planned sale
    $135K 40,000 shares at $3.37 4.1% of stake
    Traded May 7 Filed May 8
    ↗
  14. Blake Borgeson Director
    RXRXRecursion Pharmaceuticals
    Planned sale
    $106K 30,000 shares at $3.52 0.5% of stake
    Traded May 5 Filed May 7
    ↗
  15. Christopher Gibson Director
    RXRXRecursion Pharmaceuticals
    Planned sale
    $144K 40,000 shares at $3.61 4.2% of stake
    Traded Apr 22 Filed Apr 24
    ↗
  16. Christopher Gibson Director
    RXRXRecursion Pharmaceuticals
    Planned sale
    $124K 40,000 shares at $3.10 4.2% of stake
    Traded Apr 7 Filed Apr 8
    ↗
  17. Blake Borgeson Director
    RXRXRecursion Pharmaceuticals
    Planned sale
    $93K 30,000 shares at $3.10 0.5% of stake
    Traded Apr 7 Filed Apr 8
    ↗
  18. Christopher Gibson Director
    RXRXRecursion Pharmaceuticals
    Planned sale
    $130K 40,000 shares at $3.25 4.2% of stake
    Traded Mar 23 Filed Mar 25
    ↗
  19. Ben R Taylor CFO
    RXRXRecursion Pharmaceuticals
    Planned sale
    $27K 7,956 shares at $3.39 0.7% of stake
    Traded Mar 17 Filed Mar 18
    ↗
  20. Najat Khan CEO
    RXRXRecursion Pharmaceuticals
    Planned sale
    $95K 28,298 shares at $3.35 1.2% of stake
    Traded Mar 9 Filed Mar 11
    ↗
  21. Blake Borgeson Director
    RXRXRecursion Pharmaceuticals
    Planned sale
    $588K 170,000 shares at $3.46 2.6% of stake
    Traded Mar 3 Filed Mar 4
    ↗
  22. Christopher Gibson Director
    RXRXRecursion Pharmaceuticals
    Planned sale
    $138K 40,000 shares at $3.46 4.2% of stake
    Traded Feb 19 Filed Feb 19
    ↗
  23. Ben R Taylor CFO
    RXRXRecursion Pharmaceuticals
    Planned sale
    $41K 13,426 shares at $3.08 1.1% of stake
    Traded Feb 18 Filed Feb 19
    ↗
  24. Christopher Gibson Director
    RXRXRecursion Pharmaceuticals
    Planned sale
    $165K 40,000 shares at $4.12 4.2% of stake
    Traded Feb 4 Filed Feb 6
    ↗
  25. Blake Borgeson Director
    RXRXRecursion Pharmaceuticals
    Planned sale
    $924K 220,000 shares at $4.20 3.3% of stake
    Traded Feb 3 Filed Feb 6
    ↗
  26. Christopher Gibson Director
    RXRXRecursion Pharmaceuticals
    Planned sale
    $179K 40,000 shares at $4.47 4.2% of stake
    Traded Jan 20 Filed Jan 22
    ↗
  27. Blake Borgeson Director
    RXRXRecursion Pharmaceuticals
    Planned sale
    $959K 220,000 shares at $4.36 3.2% of stake
    Traded Jan 6 Filed Jan 8
    ↗
  28. Christopher Gibson Director
    RXRXRecursion Pharmaceuticals
    Planned sale
    $170K 40,000 shares at $4.25 4.1% of stake
    Traded Jan 5 Filed Jan 7
    ↗
  29. Ben R Taylor CFO
    RXRXRecursion Pharmaceuticals
    Planned sale
    $89K 21,383 shares at $4.18 2.7% of stake
    Traded Dec 29, 2025 Filed Dec 30, 2025
    ↗
  30. Najat Khan Chief R&D Commercial Officer
    RXRXRecursion Pharmaceuticals
    Planned sale
    $549K 124,403 shares at $4.41 17% of stake
    Traded Dec 22, 2025 Filed Dec 29, 2025
    ↗
  31. Christopher Gibson CEO
    RXRXRecursion Pharmaceuticals
    Planned sale
    $180K 40,000 shares at $4.50 4.2% of stake
    Traded Dec 19, 2025 Filed Dec 19, 2025
    ↗
  32. Christopher Gibson CEO
    RXRXRecursion Pharmaceuticals
    Planned sale
    $185K 40,000 shares at $4.63 4.1% of stake
    Traded Dec 4, 2025 Filed Dec 5, 2025
    ↗
  33. Blake Borgeson Director
    RXRXRecursion Pharmaceuticals
    Planned sale
    $961K 220,000 shares at $4.37 3.1% of stake
    Traded Dec 2, 2025 Filed Dec 4, 2025
    ↗
  34. Christopher Gibson CEO
    RXRXRecursion Pharmaceuticals
    Planned sale
    $166K 40,000 shares at $4.16 4.2% of stake
    Traded Nov 19, 2025 Filed Nov 19, 2025
    ↗
  35. Christopher Gibson CEO
    RXRXRecursion Pharmaceuticals
    Planned sale
    $208K 40,000 shares at $5.21 3.9% of stake
    Traded Nov 4, 2025 Filed Nov 6, 2025
    ↗
  36. Christopher Gibson CEO
    RXRXRecursion Pharmaceuticals
    Planned sale
    $570K 100,000 shares at $5.70 9.5% of stake
    Traded Oct 23, 2025 Filed Oct 24, 2025
    ↗
  37. Christopher Gibson CEO
    RXRXRecursion Pharmaceuticals
    Planned sale
    $604K 100,000 shares at $6.04 9.3% of stake
    Traded Oct 10, 2025 Filed Oct 10, 2025
    ↗

About this data

  • Officers, directors and anyone owning more than 10% of a company must report a trade in its stock on a Form 4 within two business days. We read each filing from SEC EDGAR and link to it on every row.
  • Only open-market purchases and sales of common stock count here. Stock grants, option exercises, gifts and shares withheld or sold to pay taxes on vesting awards are not decisions to buy or sell, so they are left out.
  • A planned sale was made under a Rule 10b5-1 trading plan, which the insider set up months in advance. Many executives sell this way on a schedule, so a planned sale says less than one made on the day.
  • Values are shares times the price reported. When a filing amends an earlier one, the amended trades replace the originals. Related owners (a fund and its manager) who report the same trade separately are shown once.
  • We cover the 4,839 US companies on our earnings calendar, with a year of history. The superinvestor notes count the featured 13F managers who added or cut the stock in their latest quarter.